Innovating Works

iPSC2Therapy

Financiado
From iPSC Macrophage Biology Towards Regenerative Therapies Targeting Respirator...
From iPSC Macrophage Biology Towards Regenerative Therapies Targeting Respiratory Infections Tissue resident macrophages (TRMs) can be found in various organs and fulfil important functions in host defence and tissue homeostasis. Recent studies in the murine system suggest profound tissue plasticity and self-renewal capac... Tissue resident macrophages (TRMs) can be found in various organs and fulfil important functions in host defence and tissue homeostasis. Recent studies in the murine system suggest profound tissue plasticity and self-renewal capacity of TRMs, rendering this cell population highly suitable for new cell-based therapies. Mycobacterial infections represent a serious health problem, for which new therapies are highly needed. Given the important role of alveolar macrophages (MΦs) in pulmonary host defence, I propose a cutting-edge MΦ based therapy using induced pluripotent stem cell (iPSC) technology. The unique features of iPSC will allow to investigate important regulators for the development and regenerative potential of human MΦs with the overall aim to apply these cells as an innovative treatment for pulmonary (non)tuberculous mycobacterial infections. I go beyond current knowledge and envision to enhance or exchange the endogenous alveolar MΦ cell pool by iPSC-MΦs, thereby introducing a completely new cell therapy concept. This ground-breaking cell transfer concept will have broad application potential to combat life threatening infectious diseases of the lower respiratory tract and may even be expanded to Mycobacterium tuberculosis infections. Using different knock-out iPSC lines, I will unravel important regulators for the regenerative potential of iPSC-MΦs following intra-pulmonary transfer. State-of the-art genome editing will be combined with innovative single cell RNAseq tools to understand and enhance the regenerative properties of human iPSC-MΦs. Using established cell depletion and cell transfer techniques, I will decipher the therapeutic potential of mature human iPSC-derived MΦ in vitro and in vivo using humanized mouse models and pre-clinical mycobacterial infections scenarios. The iPSC2Therapy proposal will provide an innovative anti-mycobacterial treatment with broad implications to infectious diseases and beyond. ver más
31/12/2024
MHH
1M€
Perfil tecnológico estimado
Duración del proyecto: 61 meses Fecha Inicio: 2019-11-18
Fecha Fin: 2024-12-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-11-18
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2019-STG: ERC Starting Grant
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 1M€
Líder del proyecto
MEDIZINISCHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5